Long-Term Outcomes Following Coronary Revascularizations in Diabetes Mellitus: The Emerging Role of LDL-C Thresholds
- PMID: 33153579
- DOI: 10.1016/j.jacc.2020.09.576
Long-Term Outcomes Following Coronary Revascularizations in Diabetes Mellitus: The Emerging Role of LDL-C Thresholds
Keywords: coronary artery disease; coronary revascularization; diabetes; lipids.
Conflict of interest statement
Author Relationship With Industry Dr. Navarese has received consulting fees/honoraria from Abbott, AstraZeneca, Amgen, Bayer, Sanofi, and Pfizer; and has received grants from Abbott and Amgen, outside the submitted work. Dr. Brouwer has received consulting fees/honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, and Daiichi-Sankyo, outside the submitted work. Dr. Kubica has received consulting fees/honoraria from AstraZeneca, outside the submitted work.
Comment on
-
Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization.J Am Coll Cardiol. 2020 Nov 10;76(19):2197-2207. doi: 10.1016/j.jacc.2020.09.536. J Am Coll Cardiol. 2020. PMID: 33153578
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical